Although infection with the hepatitis C virus increases health care costs overall, the specific impact of the disease’s progressive severity on health care costs has previously not been well studied.
"The severity of hepatitis C-related liver disease increases with age, and the aging hepatitis C population is likely to increase the economic burden of the infection on our health care system,” says Stuart C. Gordon, M.D., director of Hepatology at Henry Ford Hospital and lead author of the study.
The results of the study will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco this week.
It is estimated that the majority of the four million Americans with chronic hepatitis C virus infection remain undiagnosed and thus untreated. The increasing disease prevalence has created an aging population of patients with chronic hepatitis C infection and a resultant increase in the number of patients with cirrhosis, and, subsequently, the complications of cirrhosis (end-stage liver disease).
The Henry Ford study compared the economic burden for U.S. patients with chronic hepatitis C stratified by severity of liver disease in a large private health insurance claims database from 2003 to 2010. The database included claims for all prescription medications and all medical services submitted for payment.
Researchers looked at 53,796 patients with chronic hepatitis C: 41,858 (78%) without cirrhosis, 3,718 (7%) with compensated cirrhosis, and 8,220 (15%) with end-stage liver disease. Mean age was 49 years, 51 years, and 52 years respectively.
Mean health care costs (per month) were 32% and 247% higher for patients with compensated cirrhosis ($1,870) and end-stage liver disease ($4,931), compared to those without cirrhosis ($1,420) and these results were independent of age.
A similar trend is apparent for mean hepatitis C-related health care costs. Overall, 56% of total costs were hepatitis C-related and this proportion increased with disease severity (46%, 57%, and 71% for patients without cirrhosis, compensated cirrhosis, and end-stage liver disease, respectively).
Pharmacy, ambulatory, and inpatient care accounted for 90% of costs for hepatitis C patients without cirrhosis and 93% of the costs for those with compensated cirrhosis and end-stage liver disease.
The study estimated the annual health care costs to be $24,176 for patients with chronic hepatitis C infection. When looked at by disease stage, average annual costs were estimated to be $17,277 among patients with no cirrhosis, $22,752 among patients with compensated cirrhosis, and $59,995 annually among patients with end-stage liver disease.
Dr. Gordon indicated that the primary drivers of higher health care expenses were found to be inpatient costs for patients with end-stage liver disease and pharmacy costs for patients with compensated cirrhosis.
“As we see patients with more advanced liver disease, we see significantly more costs to the system. The key, therefore, is to treat and cure the infection early to prevent the consequences of more advanced disease and the associated economic burden,” says Dr. Gordon.
Current treatment for hepatitis C involves a cocktail of three drugs taken for 24-48 weeks with viral clearance “cure” rates of 65-80 percent.
Most people who are infected with hepatitis C remain without symptoms for years. The infection may lead to scarring of the liver (cirrhosis), liver cancer, the need for liver transplant, and potentially death
The study was funded by Genentech.
Maria Seyrig | EurekAlert!
Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University
New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg
Satellites in near-Earth orbit are at risk due to the steady increase in space debris. But their mission in the areas of telecommunications, navigation or weather forecasts is essential for society. Fraunhofer FHR therefore develops radar-based systems which allow the detection, tracking and cataloging of even the smallest particles of debris. Satellite operators who have access to our data are in a better position to plan evasive maneuvers and prevent destructive collisions. From April, 25-29 2018, Fraunhofer FHR and its partners will exhibit the complementary radar systems TIRA and GESTRA as well as the latest radar techniques for space observation across three stands at the ILA Berlin.
The "traffic situation" in space is very tense: the Earth is currently being orbited not only by countless satellites but also by a large volume of space...
An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.
The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...
In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.
Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...
Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.
They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...
A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...
23.03.2018 | Event News
19.03.2018 | Event News
16.03.2018 | Event News
23.03.2018 | Materials Sciences
23.03.2018 | Agricultural and Forestry Science
23.03.2018 | Physics and Astronomy